TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate in two upcoming investor conferences in September 2022. H.C. Wainwright 24th Annual Global Investment…


Previous articleAlgernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
Next articlePT354 – Laura Guzmán-Dávalos – Psilocybe, Microdosing, and Multigenerational Mycology